Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2022

Miwako Kobayashi; Jennifer L. Farrar; Ryan Gierke; Amadea Britton; Lana Childs; Andrew J. Leidner; Doug Campos‐Outcalt; Rebecca L. Morgan; Sarah S. Long; H. Keipp Talbot; Katherine A. Poehling; Tamara Pilishvili

doi:10.15585/mmwr.mm7104a1

Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2022

Authors: Miwako Kobayashi, Jennifer L. Farrar, Ryan Gierke, Amadea Britton, Lana Childs, Andrew J. Leidner, Doug Campos‐Outcalt, Rebecca L. Morgan, Sarah S. Long, H. Keipp Talbot, Katherine A. Poehling, Tamara Pilishvili - MMWR Morbidity and Mortality Weekly Report 2022 cited by 344

approach to guide its deliberations regarding use of these vaccines. Before this, PCV13 and PPSV23 were recommended for use for U.S. adults and the recommendations varied by age and risk groups. This was simplified in the new recommendations.